BROOKS

BROOKS LABORATORIES

Small Cap BSE: 533543 NSE: BROOKS
₹110.5
2.85 (2.65%)
As on 30 September, 2022 | 02:39

Brooks Laboratories Share Price

Brooks Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in BROOKS LABORATORIES

Start SIP

Brooks Laboratories Share Returns

  • Over 1 Month -14.94%
  • Over 3 Month 28.01%
  • Over 6 Month 45.32%
  • Over 1 Year -15.95%

Brooks Laboratories Key Statistics

P/E Ratio -10.8
PEG Ratio 0.3
Market Cap Cr 273
Price to Book Ratio 2
EPS 0.2
Dividend 0
Relative Strength Index 40.95
Money Flow Index 15.97
MACD Signal 3.48
Average True Range 7.32

Brooks Laboratories Investment Rating

  • Master Rating:
  • Brooks Laboratories has an operating revenue of Rs. 85.61 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of -26% needs improvement, ROE of -25% is poor and needs improvement. The company has a reasonable debt to equity of 15%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around 4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Brooks Laboratories Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 152118211615
Operating Expenses Qtr Cr 192120201518
Operating Profit Qtr Cr -40-211-4
Depreciation Qtr Cr 000002
Interest Qtr Cr 000001
Tax Qtr Cr 000007
Net Profit Qtr Cr -50-211-13

Brooks Laboratories Technicals

EMA & SMA

Current Price
110.15
2.5 (2.32%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 118.36
  • 50 Day
  • 110.95
  • 100 Day
  • 103.09
  • 200 Day
  • 95.4
  • 20 Day
  • 125.32
  • 50 Day
  • 107.03
  • 100 Day
  • 96.16
  • 200 Day
  • 95.22

Brooks Laboratories Resistance and Support

PIVOT
₹108.39
Resistance
First Resistance 111.77
Second Resistance 115.89
Third Resistance 119.27
RSI 40.96
MFI 15.97
MACD Single Line 3.48
MACD -0.17
Support
First Resistance 104.27
Second Resistance 100.89
Third Resistance 96.77

Brooks Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 10,373 1,037,300 100
Week 25,006 2,500,580 100
1 Month 50,123 5,012,319 100
6 Month 68,372 4,150,167 60.7

Brooks Laboratories Result Highlights

Brooks Laboratories Synopsis

NSE-Medical-Generic Drugs

Brooks Laboratories is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 77.25 Cr. and Equity Capital is Rs. 24.70 Cr. for the Year ended 31/03/2021. Brooks Laboratories Ltd. is a Public Limited Listed company incorporated on 23/01/2002 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24232HP2002PLC000267 and registration number is 000267.
Market Cap 272
Sales 75
Shares in Float 0.84
No of funds
Yield
Book Value 4.19
U/D Vol ratio 2.3
LTDebt / Equity 2
Alpha
Beta 1.35

Brooks Laboratories

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 66.41%66.41%66.41%
Individual Investors 28.75%28.8%28.84%
Others 4.84%4.79%4.75%

Brooks Laboratories Management

Name Designation
Mr. Atul Ranchal Chairman
Mr. Rajesh Mahajan Managing Director
Mr. Manpreet Singh Naroo Director - Technical
Mrs. Kaushalya Singh Whole Time Director
Ms. Sonia Gupta Independent Director
Mr. Deepak Mahajan Independent Director
Mr. Rajnish Kumar Bedi Independent Director

Brooks Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Brooks Laboratories Corporate Action

Date Purpose Remarks
2022-08-10 Quarterly Results
2022-05-30 Audited Results
2022-02-14 Quarterly Results
2021-11-12 Quarterly Results
2021-08-14 Quarterly Results (Revised)

Brooks Laboratories FAQs

What is Share Price of Brooks Laboratories ?

Brooks Laboratories share price is ₹110 As on 30 September, 2022 | 02:25

What is the Market Cap of Brooks Laboratories ?

The Market Cap of Brooks Laboratories is ₹273 Cr As on 30 September, 2022 | 02:25

What is the P/E ratio of Brooks Laboratories ?

The P/E ratio of Brooks Laboratories is -10.8 As on 30 September, 2022 | 02:25

What is the PB ratio of Brooks Laboratories ?

The PB ratio of Brooks Laboratories is 2 As on 30 September, 2022 | 02:25

Q1FY23